Table 1.
Study measurements at baseline and after four weeks of active treatment or placebo.
| Measurement | Intra-Subject Effects | |||
|---|---|---|---|---|
| Baseline Mean (SD) |
Final Mean (SD) |
Time | Group Time | |
| F(df); p-Value (eta2) | F(df); p-Value (eta2) | |||
| SIALOMETRY | F(1;44) = 1.045; p = 0.312 (0.023) |
F(1;44) = 0.198; p = 0.659 (0.004) |
||
| Placebo | 0.23 (0.20) | 0.24 (0.19) | ||
| Active | 0.32 (0.25) | 0.35 (0.26) | ||
| Total | 0.29 (0.23) | 0.31 (0.24) | ||
| OHIP-14 | F(1;47) = 7.948; p = 0.007 (0.145) |
F(1;47) = 3.459; p = 0.069 (0.069) |
||
| Placebo | 19.42 (9.86) | 18.89 (10.12) | ||
| Active | 20.40 (11.86) | 17.83 (9.47) | ||
| Total | 20.02 (11,03) | 18.24 (9.63) | ||
| XEROSTOMIA INVENTORY | F(1;48) = 18.327; p < 0.001 (0.276) |
F(1;48) = 4.945; p = 0.031 (0.093) |
||
| Placebo | 34.50 (9.77) | 32.75 (10.90) | ||
| Active | 33.47 (10.59) | 27.93 (8.65) | ||
| Total | 33.88 (10.18) | 29.86 (9.80) | ||
| HAD-Anxiety | F(1;43) = 4.288; p = 0.044 (0.091) |
F(1;43) = 0.01; p = 0.919 (0) |
||
| Placebo | 10.25 (5.64) | 9.69 (5.57) | ||
| Active | 9,03 (4.98) | 8.41 (4.95) | ||
| Total | 9.47 (5.19) | 8.87 (5.15) | ||
| HAD-Depression | F(1;41) = 0.271; p = 0.605 (0.007) |
F(1;41) = 1.311; p = 0.259 (0.031) |
||
| Placebo | 4.87 (4.31) | 5.53 (5.33) | ||
| Active | 5.46 (5.17) | 5.21 (4.93) | ||
| Total | 5.26 (4.84) | 5.33 (5.01) | ||